Your browser doesn't support javascript.
loading
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use.
Morandeau, Laurence; Ioppolo, Joseph A; Alvarez de Eulate, Eva; Mohamed, Shifaza; Cullen, Danica; Asad, Ali H; Francis, Roslyn J; Atkinson, Janette.
Affiliation
  • Morandeau L; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital; laurence.morandeau@health.wa.gov.au.
  • Ioppolo JA; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital; National Imaging Facility, Centre for Microscopy, Characterisation and Analysis, University of Western Australia.
  • Alvarez de Eulate E; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital.
  • Mohamed S; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital.
  • Cullen D; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital.
  • Asad AH; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital.
  • Francis RJ; National Imaging Facility, Centre for Microscopy, Characterisation and Analysis, University of Western Australia; Department of Nuclear Medicine, Sir Charles Gairdner Hospital; Medical School, University of Western Australia.
  • Atkinson J; Radiopharmaceutical Production and Development Centre (RAPID), Medical Technology and Physics Department, Sir Charles Gairdner Hospital.
J Vis Exp ; (207)2024 May 24.
Article in En | MEDLINE | ID: mdl-38856210
ABSTRACT
[68Ga]Ga-FAPI-46 is a promising new tracer for the imaging of fibroblast activation protein (FAP) by positron emission tomography (PET). Labeled FAP inhibitors (FAPIs) have demonstrated uptake in various types of cancers, including breast, lung, prostate, pancreatic and colorectal cancer. FAPI-PET also possesses a practical advantage over FDG-PET as fasting and resting are not required. [68Ga]Ga-FAPI-46 exhibits enhanced pharmacokinetic properties, improved tumor retention, and higher contrast images than the earlier presented [68Ga]Ga-FAPI-02 and [68Ga]Ga-FAPI-04. Although a manual synthesis protocol for [68Ga]Ga-FAPI-46 was initially described, in recent years, automated methods using different commercial synthesizers have been reported. In this work, we describe the development of the automated synthesis of [68Ga]Ga-FAPI-46 using the iPHASE MultiSyn synthesizer for clinical applications. Initially, optimization of the reaction time and comparison of the performance of four different solid phase extraction (SPE) cartridges for final product purification were investigated. Then, the development and validation of the production of 0.6-1.7 GBq of [68Ga]Ga-FAPI-46 were conducted using these optimized parameters. The product was synthesized in 89.8 ± 4.8% decay corrected yield (n = 6) over 25 min. The final product met all recommended quality control specifications and was stable up to 3 h post synthesis.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiopharmaceuticals / Gallium Radioisotopes Limits: Humans Language: En Journal: J Vis Exp Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Radiopharmaceuticals / Gallium Radioisotopes Limits: Humans Language: En Journal: J Vis Exp Year: 2024 Document type: Article